Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Post by stockfyon Jan 28, 2021 5:08pm
241 Views
Post# 32414217

APHA with Cipher Pharmaceuticals (CPH)?

APHA with Cipher Pharmaceuticals (CPH)?Given that the combined company APHA-TLRY will sell medicinal cannabis, I believe it could make a deal with Cipher Pharmaceuticals (CPH), which has a lot of expertise in many dermatological products.

For instance, CPH produces excellent creams for acne (i.e. its well-known Epuris has 41% market share in Canada), so CPH could make a topical ointment with medicinal cannabis for skin issues too. 

Better yet, I wish APHA acquired CPH now because CPH is profitable and dirt-cheap trading just 1.3 times its EBITDA.


And the thing is that CPH has many levers to pull for revenue growth in 2021 because it has many promising drugs in the pipeline with very positive clinical trials to-date.



<< Previous
Bullboard Posts
Next >>